1. Introduction {#sec0005}
===============

Molecular diagnostic assays such as PCR are now recognised as reliable detection methods for many viral pathogens, including foot-and-mouth disease (FMD) virus (FMDV: family *Picornaviridae*, genus *Aphthovirus*) (The World Organisation for Animal Health \[[@bib0105]\], 2012). Endemic across many countries in Asia and Africa and parts of South America, FMD is highly contagious, with outbreaks in previously disease-free areas incurring severe economic damage ([@bib0075]). Accurate and early diagnosis is therefore critical for the rapid enforcement of monitoring, control and eradication strategies. Laboratory-based real-time reverse transcription PCR (rRT-PCR) has become a widely accepted molecular tool for the detection and quantification of FMDV RNA, with diagnostic rRT-PCR assays developed for detection of all seven FMDV serotypes (A, O, C, Asia 1 and Southern African Territories \[SAT\] types 1--3) across a wide range of sample types ([@bib0010], [@bib0125]). Although relatively quick to perform, only taking a few hours to produce results ([@bib0135]), sample transportation to laboratories is required which can be lengthy and consequently delay critical decision making.

In order to address this gap, research initiatives have prioritised the transition of molecular assays into formats suitable for deployment closer to suspect cases of FMD. For instance, rRT-PCR has been transferred onto a portable platform which integrates RNA extraction, thermal cycling and result reporting ([@bib0100]), and trialled successfully in field settings ([@bib0060]). However, in order to maintain precise thermal regulation for PCR, expensive instrumentation is necessary. As an alternative, a number of isothermal chemistries have been adapted for detection of FMDV. To date, there are 17 FMDV-specific publications detailing four isothermal chemistries: reverse transcription loop-mediated isothermal amplification (\[RT-LAMP\] [@bib0040], [@bib0090], [@bib0120], [@bib0130], [@bib0015], [@bib0020], [@bib0155], [@bib0095], [@bib0055], [@bib0145], [@bib0035], [@bib0060]), reverse transcription recombinase polymerase amplification (\[RT-RPA\] [@bib0005]), nucleic acid sequence based amplification (\[NASBA\] [@bib0025], [@bib0080], [@bib0085]) and reverse transcription helicase dependent amplification (\[RT-HDA\] [@bib0070], [@bib0065]). Two of these (RT-LAMP and RT-RPA) have been transitioned into portable formats and successfully trialled in endemic settings ([@bib0005], [@bib0060]).

Understanding the diagnostic performance of new and improved assay formats is usually undertaken by pairwise concordance testing against an established reference test. Whilst this approach is useful for benchmarking assays in isolation, it does not always permit an understanding of how assays sit in the context of other similar tests. For instance, although rRT-PCR is routinely chosen as the reference test, the use of different rRT-PCR reagents, conditions and rRT-PCR cut-off values results in variations between laboratory validation studies.

Furthermore, although these isothermal assays are regularly reported as suitable for point-of-care testing (POCT) the majority of FMDV-specific isothermal assays have been validated in laboratory settings, using nucleic acid extracted using either robots or manual extraction kits not suitable for field use. A number of alternative simple sample preparation methods have been developed: preparation of serum, epithelial suspensions and oesophageal-pharyngeal (OP) fluid by dilution in nuclease-free water (NFW) has shown to produce accurate RT-LAMP results ([@bib0145], [@bib0060]) and simple elution from disposable immuno-chromatographic strip tests has been successful for sample preparation for rRT-PCR ([@bib0050]). However, these methods are yet to be compared.

In this article we present the first comparison of different isothermal assay formats for detection of FMDV, using a panel of samples benchmarked against a recommended molecular assay. Assays included representatives of RT-LAMP and RT-RPA, in addition to a selection of sample preparation methods. These tests and sample preparation methods were selected based on existing literature ([@bib0005], [@bib0060]) and because they represent the most realistic options for FMDV-specific POCT deployment.

2. Materials and methods {#sec0010}
========================

2.1. Ethics statement {#sec0015}
---------------------

All clinical samples utilised in this study were either archival samples from previous experimental studies approved by The Pirbright Institute Ethical Review Committee under the Animal Scientific Procedures Act (ASPA) 1986 (as amended), or comprised samples submitted by endemic countries to The Food and Agriculture Organization of the United Nations (FAO) World Reference Laboratory for FMD (WRLFMD) at The Pirbright Institute (TPI), UK.

2.2. Reference real-time RT-PCR (rRT-PCR) {#sec0020}
-----------------------------------------

The one-step rRT-PCR, used as the reference test, employed primers and probes as previously described to target the highly conserved 3D^pol^-coding region of the FMDV genome ([@bib0010]). Reagents, parameters and thermal cycling were as reported in [@bib0135]. rRT-PCR reactions were performed in duplicate on a bench top real-time PCR machine (Stratagene Mx3005P™: Agilent Technologies, CA, USA) ([Table 1](#tbl0005){ref-type="table"}).Table 1Molecular assay formats compared.Table 1AssayMethodReagentsReagent formSupplierPrimers and ProbesPlatformLaboratory-based rRT-PCRrRT-PCR[@bib0135]WetInvitrogen (CA, USA)[@bib0010]Mx3005P™rRT-LAMP-[d]{.smallcaps}-wetrRT-LAMPISO--001 + AMVWetOptiGene Ltd.[@bib0040]Genie^®^ IIrRT-LAMP-[d]{.smallcaps}-dryrRT-LAMPISO-001 (\*AMV included)LyophilisedOptiGene Ltd.[@bib0040][a](#tblfn0005){ref-type="table-fn"}Genie^®^ IIRT-LAMP-LFD-[d]{.smallcaps}-wetrRT-LAMP-LFDISO--001 + AMVWetOptiGene Ltd.[@bib0040]Genie^®^ IIRT-LAMP-LFD- D-dryrRT-LAMP-LFDISO-001 (\*AMV included)LyophilisedOptiGene Ltd.[@bib0040][a](#tblfn0005){ref-type="table-fn"}Genie^®^ IIrRT-LAMP-T-wetrRT-LAMPISO--001 + AMVWetOptiGene Ltd.Based on [@bib0130]Genie^®^ IIrRT-RPA-exoRTrRT-RPATwistAmp^®^ exo RTLyophilisedTwistDx Ltd.[@bib0005]Genie^®^ IIrRT-RPA-nforRT-RPATwistAmp^®^ nfo + RTLyophilisedTwistDx Ltd.[@bib0005]Genie^®^ II[^1]

2.3. RT-LAMP {#sec0025}
------------

### 2.3.1. Real-time RT-LAMP (rRT-LAMP) {#sec0030}

rRT-LAMP was performed using either [@bib0040] primers in both wet (rRT-LAMP-[d]{.smallcaps}-wet) and lyophilised (rRT-LAMP-[d]{.smallcaps}-dry) formats as previously described ([@bib0060]), or using primers from Toshiba Medical Systems Corporation \[TMSC\] (rRT-LAMP-T-wet). rRT-LAMP-T-wet was performed in a total reaction mixture of 25 μl, containing: 15 μl isothermal mastermix ISO-001 (OptiGene Ltd, Horsham, UK.), 2.5 μl TMSC FMDV primer mix (a proprietary RT-LAMP primer mix targeting the 3D^pol^-coding region), 0.15 U Avian Myeloblastosis Virus (AMV) reverse transcriptase (RT) (OptiGene Ltd.), 5 μl sample and made up to total volume with NFW. For all rRT-LAMP formats, reactions were performed in duplicate as previously described ([@bib0060]) using a Genie^®^ II (OptiGene Ltd.), with rRT-LAMP-T-wet incubated at 63 °C for 30 min. Time to positivity (T~P~) and anneal temperature (T~a~) calculations were automated using Genie^®^ Explorer v0.2.1.1 software (OptiGene Ltd.). Samples were called positive if amplification had occurred and the rRT-LAMP product annealed in the amplicon-specific temperature range (87.5--89.5 °C for Dukes et al. (2006) primers ([@bib0060]), 87.7-89.7 °C for TMSC primers)([Table 1](#tbl0005){ref-type="table"}).

### 2.3.2. RT-LAMP-D combined with lateral-flow detection (RT-LAMP-[d]{.smallcaps}-LFD) {#sec0035}

RT-LAMP-LFD was performed using both wet (*RT-LAMP-[d]{.smallcaps}-LFD-wet*) and lyophilised (*RT-LAMP-[d]{.smallcaps}-LFD-dry*) formats as previously described using modified [@bib0040] LAMP primers ([@bib0145], [@bib0060]). Reactions were performed in duplicate on a Genie^®^ II and results were visualised using PCRD-2 lateral-flow devices (Abingdon Health, York, UK) as per manufacturer's instructions and as previously described ([@bib0145], [@bib0060]). For all images shown, the upper band represents the LFD control line (C), and lower band the test line (T) in respect to the loading pad at the bottom ([Table 1](#tbl0005){ref-type="table"}).

2.4. Real-time RT-RPA (rRT-RPA) {#sec0040}
-------------------------------

### 2.4.1. TwistAmp^®^ exo RT kit (rRT-RPA-exoRT) {#sec0045}

rRT-RPA was performed using the TwistAmp^®^ exo RT kit (TwistDx Ltd., Cambridge, UK), with primers and probes as previously published ([@bib0005]). Reactions were performed in duplicate at 42 °C for 20 min using a Genie^®^ II, with inversion at 5 min to mix. T~P~ was defined when reactions reached a threshold increase of δR 1500 ([Table 1](#tbl0005){ref-type="table"}).

### 2.4.2. TwistAmp^®^ nfo (rRT-RPA-nfo) {#sec0050}

the TwistAmp^®^ nfo kit (TwistDx Ltd.) was used as manufacturer's instructions, with the addition of 10 U RT Transcriptor (Roche, Mannheim, Germany). Primers and probes were as previously published ([@bib0005]). Reactions were performed in duplicate at 39 °C for 40 min, with inversion at 4 min to mix. T~P~ was calculated as above ([Table 1](#tbl0005){ref-type="table"}).

2.5. Comparison in the relative performance of isothermal assays {#sec0055}
----------------------------------------------------------------

The analytical sensitivity of reactions was determined using an artificial RNA standard. This was produced as previously described ([@bib0060]) from *in vitro* transcription using a RT-PCR template generated from FMDV cell culture isolate O/UKG/35/2001. The standard (10^6^--10^0^ copies) was prepared in 0.1 μg/ml carrier RNA.

To determine the relative diagnostic performance of the different assays, RNA was extracted from a panel of clinical FMDV samples ([Table 2](#tbl0010){ref-type="table"}) that had previously been submitted to WRLFMD. These samples comprised 35 FMDV-positive samples, representing five serotypes (O, A, SAT 1, SAT 2 and Asia 1) from ten countries and eight epithelial suspension samples representing viruses that cause similar characteristic lesions to FMDV: swine vesicular disease virus (SVD: UKG/24/1972; UKG/50/1972; UKG/51/1972; UKG/68/1972) and two serotypes of vesicular stomatitis virus (VSV: Indiana 1 \[VSIV\] n = 2; New Jersey \[VSNJV\] n = 2). RNA was extracted using a MagMAX™-96 Viral RNA Isolation Kit (Thermo Fisher Scientific, MA, USA) following an automated procedure on a KingFisher™ Flex (Thermo Fisher Scientific). RNA was extracted from 50 μl sample and eluted in a final volume of 90 μl MagMAX™-96 Viral RNA Isolation Kit elution buffer (Thermo Fisher Scientific).Table 2FMDV clinical samples used for diagnostic comparison of isothermal assays.Table 2VirusSerotypeSampleTopotypeLineageLocationSample TypeFMDVOHKN/12/2015CATHAYunnamedHong KongESIRN/26/2015ME-SAPanAsia-2^BAL−09^IranESKUW/1/2016ME-SAPanAsia-2^BAL−09^KuwaitESKUW/4/2016ME-SAPanAsia-2^BAL−09^KuwaitESPAK/30/2015ME-SAPanAsia-2^BAL−09^PakistanESPAK/32/2015ME-SAPanAsia-2^BAL−09^PakistanESPAK/34/2015ME-SAPanAsia-2^BAL−09^PakistanESPAT/4/2015ME-SAPanAsiaPalestineESAIRN/21/2015ASIAG-VIIIranESIRN/24/2015ASIAIran-05^SIS−10^IranESSAU/8/2015ASIAG-VIISaudi ArabiaESPAK/31/2015ASIAIran-05^FAR−11^PakistanESPAK/56/2015ASIAIran-05^FAR−11^PakistanESTAN/15/2013AFRICAG-ITanzaniaESTAN/71/2012AFRICAG-ITanzaniaESSAT 1TAN/22/2014I (NWZ)unnamedTanzaniaESTAN/29/2013I (NWZ)--TanzaniaESTAN/23/2013I (NWZ)--TanzaniaESTAN/50/2012I (NWZ)unnamedTanzaniaESKEN/26/2008I (NWZ)--KenyaESKEN/9/2009I (NWZ)--KenyaESKEN/12/2009I (NWZ)--KenyaESSAT 2ZIM/9/2015IIunnamedZimbabweESZIM/21/2015IIunnamedZimbabweESTAN/3/2011IVIVTanzaniaESTAN/64/2012IVunnamedTanzaniaESTAN/14/2012IVunnamedTanzaniaESTAN/19/2012IVunnamedTanzaniaESKEN/2/2007IV--KenyaESSUD/7/2014VIIAlx-12SudanESAsia 1IRN/20/2015ASIASindh-08IranESPAK/33/2015ASIASindh-08PakistanESPAK/28/2015ASIASindh-08PakistanOFPAK/29/2015ASIASindh-08PakistanOFPAK/43/2015ASIASindh-08PakistanES[^2]

2.6. Comparison of sample preparation methodologies {#sec0060}
---------------------------------------------------

To compare sample preparation methods, three decimal dilution series (10^−1^ to 10^−8^) of FMDV (cell culture isolate O/UAE/2/2003) were prepared in bovine epithelial suspensions (cattle tongues collected from a UK abattoir were prepared at 10% \[w/v\] in M25 phosphate buffer: 35 mM Na~2~HPO~4~ , 5.7 mM KH~2~PO~4~, pH 7.6), bovine serum (obtained from a UK abattoir) and bovine OP fluid (archival experimental samples from TPI). Aliquots were stored at −80 °C until use. All sample preparation methods were performed on rRT-LAMP-[d]{.smallcaps}-wet and rRT-RPA-exoRT, adding 5 μl of template sample to each assay.

A hierarchy of sample preparation methods were selected to compare, ranging from sophisticated laboratory nucleic extraction methods to simpler methods such as dilution of samples in NFW. Three nucleic extraction methods were tested. The MagMAX™-96 Viral RNA Isolation Kit was used as the reference sample procedure (MagMAX™-96 Viral RNA Isolation Kit/KingFisher™ Flex system as described above). The kit was also evaluated using a manual protocol, following manufacturer's manual guidelines with a DynaMag™- Spin magnet (Thermo Fisher Scientific). The third extraction method evaluated was the QIAamp^®^ Viral RNA Mini Kit (Qiagen, Hilden, Germany), which was used according to manufacturer's guidelines. RNA was extracted from 140 μl of sample (using the spin column protocol) and eluted in a final volume of 60 μl in QIAamp^®^ buffer AVE (Qiagen).

In addition, a number of simple sample preparation methods were selected as they had been previously described as simple techniques for PCR inhibitor removal ([@bib0140], [@bib0110], [@bib0150], [@bib0050], [@bib0145], [@bib0060]). The simplest of techniques tested was the dilution of samples 1 in 5, 1 in 10 or 1 in 20 in NFW. Secondly, syringe filters were evaluated by diluting samples 1 in 5 in NFW and passing 1 ml of sample through a Acrodisc^®^ 25 mm syringe filter (w/0.1 um Supor^®^ Membrane) (Pall Life Sciences, MI, USA). Thirdly, Chelex^®^ 100 was evaluated by adding 50 μl of 50% (w/v) Chelex^®^ 100--500 μl of diluted sample (1 in 5 in NFW). Samples were vortexed, allowed to settle and the supernatant used in assays. For Chelex^®^ 100 (heat), samples were heated at 56 °C for 10 min prior to processing as previously stated. Finally, extraction from antigen-detection lateral-flow devices (Ag-LFDs) was evaluated (epithelial material only), by adding 200 μl of each suspension to SVANODIP^®^ FMDV-Ag-LFDs ([@bib0045]; Boehringer Ingelheim, Bracknell, UK) and incubating at room temperature (25 °C) for 72 h. Nucleic acid was extracted from the loading pad and wicking strip of the Ag-LFDs as previously described ([@bib0050]).

3. Results {#sec0065}
==========

3.1. Comparison in the performance of isothermal assays {#sec0070}
-------------------------------------------------------

The analytical sensitivities of rRT-PCR, RT-LAMP (all formats) and rRT-RPA-exoRT, using the RNA standard, were 10^1^, 10^1^, and 10^2^ copies/μl, respectively ([Fig. 1](#fig0005){ref-type="fig"}). Two log~10~ reductions in analytical sensitivity was evident for rRT-RPA-nfo compared to rRT-PCR, detecting down to 10^3^ copies/μl ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Analytical sensitivity of seven isothermal assay formats using a RNA standard. Results were compared to the diagnostic laboratory-based real-time reverse transcription (rRT)-PCR (▼). ● rRT-loop-mediated isothermal amplification using [@bib0040] primers (rRT-LAMP-D)-wet; ○rRT-LAMP-[d]{.smallcaps}-dry; ■ rRT-recombinase polymerase amplification (RPA)-exoRT;  □rRT-RPA-nfo; ▲ rRT-LAMP using Toshiba primers (rRT-LAMP-T)-wet. Half shaded points represent samples where one duplicate was positive and the other negative; grey shaded points (for rRT-PCR) represent C~T~ values that were over the diagnostic cut-off value of C~T\ \<~32 ([@bib0135]). For the molecular lateral-flow devices (LFD), the presence of a test (T) and control (C) line signifies a positive result; the presence of a single control band signifies a negative result (C). For all assays, both duplicates had to be positive for the sample to be regarded as a positive.Fig. 1

For diagnostic performance, the concordance between each isothermal assay and rRT-PCR for clinical samples (n = 43) were as follows: rRT-LAMP-[d]{.smallcaps}-wet (38/43 \[88%\]), rRT-LAMP-[d]{.smallcaps}-dry (38/43 \[88%\]), RT-LAMP-LFD-[d]{.smallcaps}-wet (37/43 \[86%\]), RT-LAMP-LFD-[d]{.smallcaps}-dry (37/43 \[86%\]), rRT-LAMP-T-wet (42/43 \[98%\]), rRT-RPA-exoRT (33/43 \[77%\]) and rRT-RPA-nfo (29/43 \[67%\]); false negative samples consistently had high rRT-PCR C~T~ values ([Fig. 2](#fig0010){ref-type="fig"}) with no false positives detected for any test. All assays yielded negative results against SVDV and VSV isolates (data not shown).Fig. 2Concordance between the diagnostic laboratory-based real-time reverse transcription (rRT)-PCR and isothermal assays using 43 clinical samples: rRT-loop-mediated isothermal amplification using [@bib0040] primes (rRT-LAMP-D)-wet (A), rRT-LAMP using Toshiba primers (rRT-LAMP-T)-wet (B), rRT-recombinase polymerase amplification (RPA)-exoRT (C) and rRT-RPA-nfo (D). Grey box highlights rRT-PCR C~T~ values over the diagnostic threshold of C~T~ \< 32 ([@bib0135]). Lyophilisation of rRT-LAMP-D did not impact assay performance.Fig. 2

3.2. Comparison of sample preparation methodologies {#sec0075}
---------------------------------------------------

Nine simple methods were compared for preparation of samples prior to molecular analysis, using the MagMAX™-96 Viral RNA Isolation Kit/KingFisher™ Flex system as the reference sample preparation procedure. For both rRT-LAMP-[d]{.smallcaps}-wet and rRT-RPA-exoRT, the use of simple extraction kits (QIAamp^®^ and MagMAX™-96 Viral RNA Isolation Kit \[manual\]) achieved comparable analytical sensitivity across all sample types to the reference sample preparation procedure ([Figs. 3](#fig0015){ref-type="fig"}A \[epithelium\], 3D \[serum\], 3G \[OP fluid\] and 4A \[epithelium\], 4D \[serum\], 4G \[OP fluid\]). For rRT-LAMP-[d]{.smallcaps}-wet, the direct use of epithelial samples (1 in 5, 1 in 10 or 1 in 20 dilution in NFW) resulted in a one log~10~ reduction in limit of detection (LOD) compared to the use of extraction kits ([Fig. 3](#fig0015){ref-type="fig"}B). When epithelial samples were eluted from Ag-LFDs (which were positive up to 10^−3^ of the dilution series) or subjected to either Chelex^®^ 100 treatment or syringe filtering (after 1 in 5 dilution in NFW), a further decrease in LOD was observed ([Fig. 3](#fig0015){ref-type="fig"}C). A one log~10~ reduction was also evident for rRT-RPA-exoRT when using epithelial samples directly (using dilution in NFW) ([Fig. 4](#fig0020){ref-type="fig"}B) compared to extracted RNA ([Fig. 4](#fig0020){ref-type="fig"}A), however non-specific amplification was evident in negative samples; this was removed by pre-processing of 1 in 5 dilutions through a syringe filter ([Fig. 4](#fig0020){ref-type="fig"}C).Fig. 3Comparison of sample preparation methods for real-time reverse transcription loop-mediated isothermal amplification using [@bib0040] primers (rRT-LAMP-[d]{.smallcaps}-wet). The top row (A-C) presents results for epithelial suspensions; the middle for serum samples (D-F); the bottom for oesophageal-pharyngeal (OP) fluid (G-I). A total of 11 sample preparation methods were trialled: (A,D,G): RNA extraction methods; (B,E,H): use of neat samples or dilution in nuclease-free water; (C,F,I): 1 in 5 dilutions subjected to further treatment using Chelex^®^ or syringe filtering. (Extraction from antigen-detection lateral-flow devices \[Ag-LFD\] was trialled for neat epithelial suspensions only) Half shaded points represent samples where one duplicate was positive and the other negative; both duplicates had to be positive for the sample to be regarded as a positive.Fig. 3Fig. 4Comparison of sample preparation methods for real-time reverse transcription recombinase polymerase amplification using TwistAmp^®^ exo RT kit (rRT-RPA-exoRT). Sample preparation methods were trialled across three sample types: epithelial suspensions (A-C), serum samples (D-F) and oesophageal-pharyngeal (OP) fluid (G-I). Eleven sample preparation methods were tested: (A,D,G): RNA extraction methods; (B,E,H): use of neat samples or dilution in nuclease-free water; (C,F,I): 1 in 5 dilutions subjected to Chelex^®^ or syringe filtering (antigen-detection lateral-flow devices \[Ag-LFD\] extraction was trialled for neat epithelial suspensions only). NS: non-specific amplification detected (signified by amplification present in known negative samples); AI: assay inhibition. Half shaded points represent samples where one duplicate was positive and the other negative; both duplicates had to be positive for the sample to be regarded as a positive.Fig. 4

For serum, a two log~10~ reduction in LOD was evident when serum was diluted prior to analysis in rRT-LAMP-[d]{.smallcaps}-wet ([Fig. 3](#fig0015){ref-type="fig"}E) compared to the use of extracted RNA ([Fig. 3](#fig0015){ref-type="fig"}D). When serum was added neat to reactions rRT-LAMP-[d]{.smallcaps}-wet was inhibited ([Fig. 3](#fig0015){ref-type="fig"}E). Following 1 in 5 dilution of serum in NFW, the use of Chelex^®^ 100 (heat) improved LOD, with only a one log~10~ reduction in LOD evident compared to the use of extracted RNA ([Fig. 3](#fig0015){ref-type="fig"}F). For rRT-RPA-exoRT, the use of simple sample preparation techniques for serum resulted in assay inhibition ([Fig. 4](#fig0020){ref-type="fig"}E and 4F), with extraction required (using any of the three RNA extraction methods tested) in order for amplification to be observed ([Fig. 4](#fig0020){ref-type="fig"}D).

For OP fluid, again a two log~10~ reduction in LOD for rRT-LAMP-[d]{.smallcaps}-wet was evident when OP fluid was diluted in NFW (1 in 10 or 1 in 20) prior to analysis ([Fig. 3](#fig0015){ref-type="fig"}H), compared to the use of extracted RNA ([Fig. 3](#fig0015){ref-type="fig"}G). Neat OP fluid and OP fluid samples diluted 1 in 5 (with or without Chelex^®^ 100 treatment or syringe filtering), reduced the analytical sensitivity of rRT-LAMP-[d]{.smallcaps}-wet ([Fig. 3](#fig0015){ref-type="fig"}H and 3I), with a three log~10~ reduction in LOD evident compared to the use of extracted RNA. For rRT-RPA-exoRT, extraction of RNA from OP fluid was required ([Fig. 4](#fig0020){ref-type="fig"}G), with the use of simple sample preparation methods (either neat, using dilutions \[with or without Chelex^®^ 100 or syringe filter treatment\]) resulting in assay inhibition ([Fig. 4](#fig0020){ref-type="fig"}H and I).

4. Discussion {#sec0080}
=============

The requirement for rapid and accurate diagnosis of FMD has led to an increased interest in evaluating simple-to-use diagnostic platforms that can be deployed closer to suspect cases of FMD. For instance, field-ready rRT-PCR, rRT-LAMP, RT-LAMP-LFD and rRT-RPA have been successfully trialled in endemic settings, allowing for accurate detection of FMDV *in situ* ([@bib0005], [@bib0060]). However, based on the lack of formal comparisons between these different assays, in addition to the lack of standardisation in assay evaluation, it is difficult to accurately gauge the best isothermal test based on independent publications at present. This manuscript details a comparison of multiple isothermal chemistries, assay formats and sample preparation procedures for detection of FMDV.

The analytical sensitivities of isothermal assays were equivalent to previously published results when using an FMDV RNA standard, with all RT-LAMP assay formats showing comparable analytical sensitivity to rRT-PCR ([@bib0145], [@bib0060]) and rRT-RPA-exoRT displaying a one log~10~ reduction in sensitivity ([@bib0005]). However in this study, the template of choice impacted upon assay performance with more variation evident between assays when assessing relative diagnostic sensitivity using RNA extracted from clinical samples. This is likely due to the absence of host-derived nucleic acid and/or absence of nucleic acid structures present in a RNA standards, however further work is required to confirm this. These results should be considered by researchers when evaluating new assays, to prevent the false overestimation of sensitivity and performance if this is determined using a RNA standard only.

Consistent with [@bib0155] who evaluated [@bib0130] primers and probes (TMSC primers are based on these), rRT-LAMP-T-wet displayed the highest sensitivity of all isothermal assays, however at present this assay has only been evaluated in a wet format suitable for laboratory settings. As previously published by [@bib0060], lyophilisation of rRT-LAMP-D and RT-LAMP-LFD-D reagents did not impact on the assay sensitivity or specificity; similar work needs to be carried out for rRT-LAMP-T-wet to transition this assay into a format suitable for field use. For rRT-RPA, the TwistAmp^®^ exo RT kit displayed better performance than the TwistAmp^®^ nfo kit, likely due to the addition of Exonuclease III, which contains 3ʹ-5ʹ exonuclease activity, enhancing fluorescent probe degradation during amplification. However, rRT-RPA assays consistently had reduced sensitivity compared to all RT-LAMP formats; previous studies have shown that the additional RT enzyme (RT 'Transcriptor', Roche) to the TwistAmp^®^ exo RT kit helped to increase assay sensitivity ([@bib0005]), however this requires maintenance of the cold chain and is consequently less suitable for field-based assays.

Sample preparation remains the bottleneck of *in situ* nucleic acid detection, with current procedures being complex, time-consuming and requiring both dedicated laboratory spaces and specialised equipment ([@bib0030]). This manuscript also presents a comparison of different simple sample preparation techniques across two isothermal assays. For both rRT-LAMP-[d]{.smallcaps}-wet and rRT-RPA-exoRT, both manual nucleic extraction kits gave comparable analytical sensitivity to automated extraction across all sample types. However, the requirement for multiple stages limits the use of these to laboratory settings, with more direct procedures required for field-based detection of FMDV.

rRT-RPA-exoRT displayed poor tolerance to inhibitors, with both sera and OP fluid inhibiting assays when added in the absence of RNA extraction. For epithelial suspensions, amplification in the rRT-RPA-exoRT assay was evident following dilution of the samples, however syringe filters were required to prevent non-specific amplification. Previous studies have indicated that LAMP shows increased tolerance to inhibitors compared to PCR ([@bib0115], [@bib0145]). In this study, rRT-LAMP was performed in the absence of RNA extraction for multiple sample types (epithelial suspensions, sera and OP fluid). However, the analytical sensitivity of rRT-LAMP reactions was reduced when using simple sample preparation methods compared to RNA extraction. For instance, simple dilution of epithelial suspensions in NFW (1 in 5, 1 in 10 or 1 in 20) resulted in an one log~10~ decrease in sensitivity, consistent with the dilution factor. For serum, the use of Chelex^®^ 100 (plus a heat stage) produced the best results for direct rRT-LAMP-[d]{.smallcaps}-wet, with a one log~10~ decrease in sensitivity compared to extraction methods (again consistent with dilution factor and previous publications ([@bib0060])). Chelex^®^ 100 has previously been reported as an extraction method for serum, as the ion-exchange resin removes the effect of inhibitors ([@bib0140], [@bib0110]); the same effect was not seen for the other sample types. Direct sample preparation methods for OP fluid resulted in a two log~10~ decrease in the rRT-LAMP-[d]{.smallcaps}-wet assay LOD compared to extraction methods, suggesting partial assay inhibition in addition to the effects of dilution factor, consistent with previous publications ([@bib0060]).

Although the evaluation of assay performance is specific to the conditions/primers tested in this analysis, the compatibility of RT-LAMP chemistry with numerous sample types offers advantages over current point of care tests by being able to detect FMDV across a larger diagnostic window of detection, in addition to displaying increased analytical sensitivity. For example, Ag-LFDs only offer equivalent diagnostic sensitivity to laboratory-based Ag-ELISAs ([@bib0045]), which limits their application to the acute clinical phase of disease and samples which contain high amounts of intact virus particles (epithelium and vesicular fluid only).

5. Conclusions {#sec0085}
==============

In conclusion, this manuscript presents the first side-by-side analysis of multiple isothermal assay formats in order to define their current capabilities benchmarked against rRT-PCR. RT-LAMP assays are comparable to the diagnostic rRT-PCR when considering a cut-off value and using extraction methods. Significantly, for RT-LAMP there was only a one log~10~ reduction in sensitivity when RNA extraction was negated for epithelial tissue suspensions (diluted 1 in 5) and serum samples (treated with Chelex^®^ 100 \[heat\]). RT-RPA was not as sensitive as rRT-PCR (using RNA extraction), and when used in the absence of extraction techniques was prone to inhibition across OP fluid and serum samples. With standard extraction techniques not a viable option for pen-side testing, the ability to perform RT-LAMP in the absence of RNA extraction over a large diagnostic detection window, provides a realistic means to rapidly confirm positive FMD cases close to the point of sampling.
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[^1]: Primers, probes and Avian Myeloblastosis Virus (AMV) were lyophilised within LAMP reagents. (rRT): real-time reverse transcription; (LAMP): loop-mediated isothermal amplification using either (D) [@bib0040] or (T) Toshiba Medical Systems Corporation primers; (LFD): molecular lateral-flow device; (RPA) recombinase polymerase amplification using either (exoRT) TwistAmp^®^ exo RT or (nfo) TwistAmp^®^ nfo reagents; (RT) reverse transcriptase.

[^2]: (FMDV): foot-and-mouth disease virus; ES (epithelial suspension); OF (oral fluid).
